Literature DB >> 16581093

Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain.

Anne Amphoux1, Vincent Vialou, Eva Drescher, Michael Brüss, Clotilde Mannoury La Cour, Catherine Rochat, Mark J Millan, Bruno Giros, Heinz Bönisch, Sophie Gautron.   

Abstract

Organic cation transporters (OCTs) are polyspecific carriers implicated in low-affinity, corticosteroid-sensitive extraneuronal catecholamine uptake in peripheral tissues. The three main OCT subtypes, OCT1, OCT2 and OCT3, are also present in the brain, but their central role remains unclear. In the present study, we investigated by comparative in situ hybridization analysis the regional distribution of these transporters in rat brain and compared their functional properties in stably transfected HEK293 cells expressing human or rat OCTs. In rat brain, OCT2 and OCT3 mRNAs are expressed predominantly in regions located at the brain-cerebrospinal fluid border, with OCT3 mRNA expression extending to regions that belong to monoaminergic pathways such as raphe nuclei, striatum and thalamus. After normalization with MPP+ uptake, OCT2 and OCT3 subtypes share a similar monoamine preference profile, with higher transport efficacies for epinephrine and histamine than for the other monoamines. Interestingly, a significant level of epinephrine transport, previously only shown for rOCT2, is achieved by most OCTs subtypes. Finally, another novel finding was that OCTs are sensitive to 3,4-methylenedioxymetamphetamine (MDMA), phencyclidine (PCP), MK-801 and ketamine. Altogether, all our results suggest a functional specialization of OCT subtypes, based both on their intrinsic properties and their differential regional expression pattern in the brain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16581093     DOI: 10.1016/j.neuropharm.2006.01.005

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  75 in total

1.  Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3.

Authors:  Phillip M Rappold; Mei Cui; Adrianne S Chesser; Jacqueline Tibbett; Jonathan C Grima; Lihua Duan; Namita Sen; Jonathan A Javitch; Kim Tieu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

2.  Common drugs inhibit human organic cation transporter 1 (OCT1)-mediated neurotransmitter uptake.

Authors:  Kelli H Boxberger; Bruno Hagenbuch; Jed N Lampe
Journal:  Drug Metab Dispos       Date:  2014-03-31       Impact factor: 3.922

3.  Organic cation transporter inhibition increases medial hypothalamic serotonin under basal conditions and during mild restraint.

Authors:  Na Feng; Christopher A Lowry; Jodi L Lukkes; Miles Orchinik; Gina L Forster; Kenneth J Renner
Journal:  Brain Res       Date:  2010-02-19       Impact factor: 3.252

4.  Decynium-22 enhances SSRI-induced antidepressant-like effects in mice: uncovering novel targets to treat depression.

Authors:  Rebecca E Horton; Deana M Apple; W Anthony Owens; Nicole L Baganz; Sonia Cano; Nathan C Mitchell; Melissa Vitela; Georgianna G Gould; Wouter Koek; Lynette C Daws
Journal:  J Neurosci       Date:  2013-06-19       Impact factor: 6.167

5.  Antidepressant efficacy of a selective organic cation transporter blocker in a mouse model of depression.

Authors:  Alejandro Orrico-Sanchez; Laetitia Chausset-Boissarie; Rodolphe Alves de Sousa; Basile Coutens; Sara Rezai Amin; Vincent Vialou; Franck Louis; Assia Hessani; Patrick M Dansette; Teodoro Zornoza; Carole Gruszczynski; Bruno Giros; Bruno P Guiard; Francine Acher; Nicolas Pietrancosta; Sophie Gautron
Journal:  Mol Psychiatry       Date:  2019-10-16       Impact factor: 15.992

6.  Effects of chronic caffeine exposure during adolescence and subsequent acute caffeine challenge during adulthood on rat brain serotonergic systems.

Authors:  M R Arnold; P H Williams; J A McArthur; A R Archuleta; C E O'Neill; J E Hassell; D G Smith; R K Bachtell; C A Lowry
Journal:  Neuropharmacology       Date:  2018-12-20       Impact factor: 5.250

7.  OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children.

Authors:  Rajiv Balyan; Xue Zhang; Vidya Chidambaran; Lisa J Martin; Tomoyuki Mizuno; Tsuyoshi Fukuda; Alexander A Vinks; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2017-05-04       Impact factor: 2.533

Review 8.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

9.  Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2.

Authors:  Jaclyn N Harper; Stephen H Wright
Journal:  Am J Physiol Renal Physiol       Date:  2012-10-03

10.  Interaction of the human plasma membrane monoamine transporter (hPMAT) with antidepressants and antipsychotics.

Authors:  Britta Haenisch; Heinz Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.